Quick Takeaways
- BlackRock, Inc. filed SCHEDULE 13G for Eledon Pharmaceuticals, Inc. Common Stock (ELDN).
- Disclosed ownership: 5.8%.
- Date of event: 31 Mar 2026.
BlackRock, Inc. - 31 Mar 2026 SCHEDULE 13G Report for Eledon Pharmaceuticals, Inc. Common Stock (ELDN)
- Filing Manager
- BlackRock, Inc.
- Reporting Manager
- BlackRock, Inc.
- Symbol
- ELDN
- Shares outstanding
- 75,532,017 shares
- Disclosed Ownership
- 4,380,857 shares
- Ownership
- 5.8%
- Form type
- SCHEDULE 13G
- Filing time
- 27 Apr 2026, 16:12:23 UTC
- Date of event
- 31 Mar 2026
- Previous filing
- 21 Jan 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"BlackRock, Inc. disclosed 5.8% ownership in Eledon Pharmaceuticals, Inc. Common Stock (ELDN) on 31 Mar 2026."
What Changed
- Previous schedule filing date: 21 Jan 2026.
- Current filing was accepted on 27 Apr 2026, 16:12.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 5.8% | 4,380,857 | 4,324,348 | 0 | Spencer Fleming | Managing Director |